Exact Mass: 335.06026860000003

Exact Mass Matches: 335.06026860000003

Found 41 metabolites which its exact mass value is equals to given mass value 335.06026860000003, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Dihydroneopterin phosphate

[(2R,3S)-3-(2-amino-4-oxo-1,4,7,8-tetrahydropteridin-6-yl)-2,3-dihydroxypropoxy]phosphonic acid

C9H14N5O7P (335.06308240000004)


Dihydroneopterin phosphate is involved in the folate biosynthesis pathway. Dihydroneopterin phosphate is produced from 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine. triphosphate by [E3.6.1.-]. Dihydroneopterin phosphate is then converted to Dihydroneopterin by [E3.6.1.-]. Dihydroneopterin phosphate is involved in the folate biosynthesis pathway. Dihydroneopterin phosphate is produced from 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine

   

sulfanitran

sulfanitran

C14H13N3O5S (335.0575888)


C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

   
   

isoxicam

4-hydroxy-2-methyl-N-(5-methyl-2,3-dihydro-1,2-oxazol-3-ylidene)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide

C14H13N3O5S (335.0575888)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

2-Methyl-N-(5-methyl-3-isoxazolyl)-1,1,4-trioxo-3H-1$l^{6},2-benzothiazine-3-carboxamide

2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1,4-trioxo-3,4-dihydro-2H-1lambda6,2-benzothiazine-3-carboxamide

C14H13N3O5S (335.0575888)


   

isoxicam

isoxicam

C14H13N3O5S (335.0575888)


A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome. C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   
   
   
   

beta-Nicotinamide D-ribonucleotide

1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-3-(C-hydroxycarbonimidoyl)-1$l^{5}-pyridin-1-ylium

C11H16N2O8P (335.0644246)


   

4-(4-chloro-3,5-dimethylphenoxy)-N-hydroxy-3-nitrobenzenecarboximidamide

4-(4-chloro-3,5-dimethylphenoxy)-N-hydroxy-3-nitrobenzenecarboximidamide

C15H14ClN3O4 (335.0672794)


   

6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt

6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt

C17H14NNaO3S (335.0592054)


   

6-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID

6-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID

C17H9F4NO2 (335.0569382)


   

8-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID

8-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID

C17H9F4NO2 (335.0569382)


   

(+/-)-N,N-DIMETHYL-1-FERROCENYLETHYLAMINE

(+/-)-N,N-DIMETHYL-1-FERROCENYLETHYLAMINE

C16H18BrNO2 (335.0520828)


   

4-AMINO-6-PHENYLPYRIMIDINE

4-AMINO-6-PHENYLPYRIMIDINE

C16H14ClNO5 (335.0560464)


   

3-carboxy-5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid

3-carboxy-5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid

C16H14ClNO5 (335.0560464)


   

5-Bromo-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

5-Bromo-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole

C15H19BBrNO2 (335.0692124)


   

2,3-dimethylbenzothiazolium p-toluenesulphonate

2,3-dimethylbenzothiazolium p-toluenesulphonate

C16H17NO3S2 (335.0649812)


   

chlordiazepoxide hydrochloride

chlordiazepoxide hydrochloride

C16H15Cl2N3O (335.059212)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

   

methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate

methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate

C16H18BrNO2 (335.0520828)


   

sulfachrysoidine

sulfachrysoidine

C13H13N5O4S (335.0688218000001)


C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent

   

5-Formyl-2-deoxy-cytidine-5-monophosphate

5-Formyl-2-deoxy-cytidine-5-monophosphate

C10H14N3O8P (335.05184940000004)


   
   

N-(1,1-dioxo-3-thiolanyl)-N-(thiophen-2-ylmethyl)benzamide

N-(1,1-dioxo-3-thiolanyl)-N-(thiophen-2-ylmethyl)benzamide

C16H17NO3S2 (335.0649812)


   

[(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

[(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

C11H16N2O8P+ (335.0644246)


   

Nicotinamide ribotide

3-carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1lambda5-pyridin-1-ylium

C11H16N2O8P+ (335.0644246)


Nicotinamide ribotide (NMN) (CAS: 1094-61-7) is an important intermediate metabolite in the nicotinate and nicotinamide metabolism pathway. Mammals predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis. Instead of the deamidation into nicotinic acid, nicotinamide is directly converted into NMN by nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12). The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1), which is a member of the nucleotidyltransferase alpha/beta-phosphodiesterase superfamily, catalyzes the reaction NMN + ATP <=> nicotinamide adenine dinucleotide (NAD) + PPi, representing the final step in the biosynthesis of NAD. NAD is a molecule that plays a fundamental role as a cofactor in cellular redox reactions. Thus NMN is an important metabolite for the maintenance of normal NAD biosynthesis. Circulating NMN levels may play an important role in regulating cell function in physiological and pathophysiological conditions (PMID: 15078171, 17983582). Nicotinamide ribotide (NMN) is an important intermediate metabolite in the nicotinate and nicotinamide metabolism pathway. Mammals predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis. Instead of the deamidation to nicotinic acid, nicotinamide is directly converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12). The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1), a member of the nucleotidyltransferase alpha/beta-phosphodiesterase superfamily, catalyzes the reaction NMN + ATP = Nicotinamide adenine dinucleotide (NAD) + PPi, representing the final step in the biosynthesis of NAD, a molecule playing a fundamental role as a cofactor in cellular redox reactions. Thus NMN is an important metabolite for the maintenance of normal NAD biosynthesis, and circulating NMN levels may play an important role in regulating cell function in physiological and pathophysiological conditions. (PMID: 15078171, 17983582) [HMDB]

   
   
   

S-nitrosoglutathione(1-)

S-nitrosoglutathione(1-)

C10H15N4O7S- (335.066142)


D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors > D026403 - S-Nitrosothiols D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D020030 - Nitric Oxide Donors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000890 - Anti-Infective Agents D020011 - Protective Agents

   

2-Methyl-N-(5-methyl-3-isoxazolyl)-1,1,4-trioxo-3H-1$l^{6},2-benzothiazine-3-carboxamide

2-Methyl-N-(5-methyl-3-isoxazolyl)-1,1,4-trioxo-3H-1$l^{6},2-benzothiazine-3-carboxamide

C14H13N3O5S (335.0575888)


   

(R)-SKF 38393 hydrobromide

(R)-SKF 38393 hydrobromide

C16H18BrNO2 (335.0520828)


   

(S)-SKF 38393 hydrobromide

(S)-SKF 38393 hydrobromide

C16H18BrNO2 (335.0520828)


   

[(2R,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

[(2R,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

C11H16N2O8P+ (335.0644246)


   

[7-[(3-Cyanophenyl)sulfonylamino]-4-methylindol-3-ylidene]methylideneazanide

[7-[(3-Cyanophenyl)sulfonylamino]-4-methylindol-3-ylidene]methylideneazanide

C17H11N4O2S- (335.06026860000003)


   
   

beta-Nicotinamide ribose monophosphate

beta-Nicotinamide ribose monophosphate

C11H16N2O8P+ (335.0644246)